

ML2038/BfrA Recombinant Protein from *Mycobacterium leprae*

Catalog No. NR-19337

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor and Manufacturer:

NIH – Leprosy Research Support Contract

Product Description:

NR-19337 is a recombinant form of the bacterioferritin protein (ML2038/BfrA) [also known as major membrane protein II (MMP-II) and 22 kDa protein] from *Mycobacterium leprae*. The recombinant His-tagged protein was expressed in *Escherichia coli*, strain BL21(DE3)pLysS and purified using standard chromatographic techniques followed by endotoxin removal procedures.

Material Provided:

Each vial contains approximately 0.5 mg of lyophilized NR-19337 in 10 mM ammonium bicarbonate.

Note: NR-19337 is soluble in 100 mM to 500 mM aqueous buffered salt solutions, such as phosphate buffered saline. A 10 mM ammonium bicarbonate solution can also be used.

Packaging/Storage:

NR-19337 was packaged aseptically in screw-cap cryovials. The product is provided frozen on dry ice and should be stored at -80°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: ML2038/BfrA Recombinant Protein from *Mycobacterium leprae*, NR-19337."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Cole, S. T., et al. "Massive Gene Decay in the Leprosy Bacillus." Nature 409 (2001): 1007-1011. PubMed: 11234002.
2. Hunter, S. W., et al. "The Major Proteins of the Leprosy Bacillus." J. Biol. Chem. 365 (1990): 14065-14068. PubMed: 2201679.
3. Lahiri, R., et al. "Development of a Mouse Foot Pad Model for Detection of Sub Clinical Leprosy." Lepr. Rev. 83 (2011): 432-444. PubMed: 22439282.
4. Pessolani, M. C., et al. "Purification, Characterization, Gene Sequence, and Significance of a Bacterioferritin from *Mycobacterium leprae*." J. Exp. Med. 180 (1994): 319-327. PubMed: 8006590.
5. Spencer, J. S., et al. "Analysis of Antibody Responses to *Mycobacterium leprae* Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins to Define Disease Subtype-Specific Antigenic Profiles in Leprosy." Clin. Vaccine Immunol. 18 (2011): 260-267. PubMed: 21177913.

ATCC® is a trademark of the American Type Culture Collection.

